The U.S. Food and Drug Administration (FDA) has approved Journavx, the first opioid-free prescription drug for moderate to ...

A top administration official said that, without new declines, tariffs on Canada and Mexico were appropriate. But the kind of ...

The FDA has approved label changes for once-monthly Sublocade, helping to reduce possible barriers to treatment initiation ...

The leader of the nonprofit Project Opioid says steps Palm Beach County has taken are working, in light of the number of ...

Feb. 25, 2025 – The FDA has approved a new treatment plan for a long-acting injection, making it easier for people with moderate to severe opioid use disorder (OUD) to start and keep up with ...

LTG-001, a selective inhibitor for treatment of acute pain, was granted Fast Track designation by the Food and Drug Administration (FDA).

Despite not differentiating itself from placebo, the Texas-based company said it plans to push pilavapadin into Phase III ...

In Australia, more than 40,000 people are imprisoned every day. More than half of these people experience drug addiction, ...

Indivior said the U.S. Food and Drug Administration approved label changes for its opioid-dependence treatment Sublocade, including a rapid initiation protocol and alternative injection sites.

A Kentucky county nestled in the heart of Appalachia, where the opioid crisis has wreaked devastation for decades, spent ...

On January 30, the U.S. Food and Drug Administration approved Journavx (suzetrigine) 50 milligram oral tablets, a first-in-class non-opioid ...